The MASH Research Study

Currently Recruiting

8 Sep 2026

Up to $10,000

Brisbane, Australia

Metabolic dysfunction-associated steatohepatitis (MASH), previously known as non-alcoholic steatohepatitis (NASH), is a progressive liver condition linked to obesity, insulin resistance, and high cholesterol. It can lead to serious complications such as progressive liver disease and liver cancer. 

Current treatment options are limited and often rely on lifestyle changes like diet and exercise. While some medications exist, they don’t work for everyone, highlighting the need for new therapies. 

This clinical trial is evaluating a potential new injectable medication designed to activate two important pathways in the body that help regulate metabolism, reduce liver fat, and improve insulin sensitivity. These pathways are known to play a role in managing metabolic disorders and liver inflammation. 

Apply now Speak with us 1300 644 028

Join our clinical trial

We are conducting this first-in-human (FIH) study to assess the safety, tolerability, and how the body processes the investigational treatment in healthy and overweight or obese adult volunteers. This is a vital early step before the treatment can be tested in patients with liver disease. 

This FIH study has been carefully designed with strict safety protocols. Before participating, you will receive detailed information about the study, its procedures, and how risks are managed. You’ll also meet with one of our doctors to discuss any questions you may have.

Why participate?

  • Help advance research into a potential new treatment for liver disease and metabolic disorders. 
  • Be part of early-stage research that could benefit people with limited treatment options. 
  • Contribute to the development of a therapy that targets a different pathway than existing medications. 
  • Your involvement helps researchers gather essential data that could inform future therapies. 

Study schedule

 

Intake 1 In-clinic stay:

Stay 1

8 September 2026 – 11 September 2026

Stay 2

15 September 2026 – 17 September 2026

Stay 3

22 September 2026 -24 September 2026

Stay 4

29 September 2026- 1 October 2026

Stay 5

6 October 2026 – 9 October 2026

 Follow-up visits:

13 September 2026
11 October 2026
14 October2026
21 October 2026
28 October 2026

Study dates are subject to change. Our team will confirm details with you during the screening process.

Trial details

Study duration

  • 2 screening visits
  • 12 night inpatient stay (split into 2 nights  x 3, 3 nights x 2)
  • 5 follow-up visits

Study medication

The study drug will be administered as a subcutaneous injection.

Additional eligibility

• Weight  <130kg

• Stable body weight <5kg change during the 90 days before Screening

• Non-smokers or no smoking within 2months before Screening

 

Ethics

The study has been carefully designed with strict safety protocols and has been approved by an independent ethics committee.

Are you a match?

Age

18 - 65 years old

Remuneration

Up to $10,000 *with screening reimbursement.
Full details outlined in consent form.

Gender

Male, Female, Female (Post-menopausal) or Female of non-childbearing potential

BMI

BMI 30 - 45 kg/m2

Commitment

12 nights, 5 clinic visits

Medical condition

Not taking any medications

Register your interest

This form takes around 3–5 minutes to complete. Your information will remain confidential and is used only to assess your eligibility for current or future research studies.
Step 1 of 3
Contact Information




The phone number you have entered does not appear to be a valid active Australian phone number. Please check your details and enter a valid Australian phone number starting with +61

Nucleus Network does not currently conduct clinical trials in your state. If you would like to receive study information should this situation change, please complete and submit this form.
Personal Information

This includes registering your interest with the Centre for Clinical Studies, Q-Pharm or Nucleus Network

Please call us on 1800 243 733


What is your date of birth?
Day Month Year

You need to be at least 18 years old to participate in clinical trials.


cm

kg






















Step 2 of 3
Medical History

We regularly have studies that allow participants who are (social) smokers.

We define an allergy as severe if symptoms include mouth/throat/face swelling, shortness of breath or a whole-body rash, or if it required hospitalisation

We regularly have studies that allow for/require participants with asthma.



We regularly have studies that allow for/require participants with medical conditions.

Medications & Contraception Requirements

We regularly have studies that allow participants with depression that is well-managed on a stable dose of medication.

If the only prescription medication you currently use is hormonal contraception and/or Ventolin, please select No above. We regularly have studies that allow for participants who take a stable dose of prescription medication.


  • Abstinence from sex with anyone of the opposite sex for at least 2 months
  • Using a condom + your female sexual partner(s) using a separate form of birth control
  • You or your sexual partner(s) had a vasectomy/hysterectomy
  • Your sexual partner(s) are post-menopausal


Only you taking birth control or your partner(s) using a condom is not an acceptable option, but using both together is. The morning after pill is not an acceptable form of birth control.

  • Abstinence, by choice, from sex with anyone of the opposite sex for the last 2 months + remaining abstinent for at least 2 months after study participation
  • You using birth control + your male sexual partner(s) using a condom
  • You or your sexual partner(s) had a hysterectomy/vasectomy
  • You are post-menopausal



Step 3 of 3
Study Preferences

While longer studies generally have a higher reimbursement, there are also studies with multiple short stays that have high reimbursements.
Referral Information


Consent to Information Use and Future Contact